Company

Federal Bank (FBL) reported 3QFY19 results with the key takeaways being: (1) MSME slippage of Rs 1.92bn looks somewhat concerning but incremental NPA formation from MSME would be mitigated from 4QFY19 onwards due to RBI dispensation.
Jan. 18, 2019, 11:36 a.m.
Publisher: nirmalbang.com

Video article on Analysing Wipro's Earnings.
Jan. 18, 2019, midnight
Publisher: youtube.com

GMR Airports is in discussions with Malaysia Airports Holding Berhad (MAHB) to explore the possibility of entering into a fresh agreement for buying the latter’s 11 per cent stake in GMR Hyderabad Int
Jan. 17, 2019, 3:36 p.m.
Publisher: thehindubusinessline.com

IATA also feels that the Indian ecosystem needs to support the sustainability of airlines in the country.
Jan. 17, 2019, 2:34 p.m.
Publisher: thehindubusinessline.com

Earning per share (EPS) of the company for the earnings for FY19E and FY2oE is seen at Rs. 31.18 and Rs. 38.51 respectively. Net Sales and PAT of the company are expected to grow at a CAGR of 23% and 34% over 2017 to 202oE respectively.
Jan. 17, 2019, 12:28 p.m.
Author : Firstcall India Equity | Publisher: indianotes.com

Earning per share (EPS) of the company for the earnings for FY19E and FY2oE is seen at Rs. 24.71 and Rs. 30.25 respectively. Net Sales and Operating Profit of the company is expected to grow at a CAGR of 20% and 45% over 2017 to 202oE respectively.
Jan. 17, 2019, 12:21 p.m.
Author : Firstcall India Equity | Publisher: indianotes.com

Q3FY19 results of the bank were in-line with our expectatons PAT grew by 30% yoy to ₹ 3.3 bn. Balance sheet growth was strong credit grew by 24% yoy led by corporate and retail loans.
Jan. 17, 2019, 12:11 p.m.
Author : LKP Research | Publisher: indianotes.com

We initiated on Dilip Buildcon (DBL) on April, 2017 with hypothesis of strong growth, good order book and improvement in balance sheet. However, the current stress in liquidity scenario and stress on the balance sheet has made us cautious and we recommend an exit at the current juncture.
Jan. 17, 2019, 11:35 a.m.
Publisher: edelweiss.in

Aurobindo Pharma (ARBP) would acquire seven marketed oncology products, intellectual property and commercial infrastructure from Spectrum Pharma for a consideration of USD300m, which includes an upfront payment of USD160m and a milestone-linked payment of USD140m.
Jan. 17, 2019, 11:32 a.m.
Publisher: motilaloswal.com

Jan. 17, 2019, 11:28 a.m.
Publisher: nirmalbang.com